The FDA ambushed Amarin at the ADCOM. That is different than a readout of results from a trial. Vascepa is on the market. And there is continued sales growth because it is working. Had FDA played fair and not pulled the rug out on Amarin and the SPA, the dilutions would not have been necessary.
I agree with some of what you say.What I have learned from amarin and another stock called elan is that the people in the company can make huge money by running a lengthy trial for years and gain large salaries and options,the only people that loose everything is the investor.Hopefully im wrong on this occasion.Best of luck